2024 Georgia Tumor Markers Testing Market--High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

May 2024 | | ID: 2BED7FECCA55EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.The report is available by section, and can be customized to specific information needs and budget.The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

• Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

Contents

I. Introduction
II. Market Overview
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Major Current and Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. CANCER DIAGNOSTIC CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRIONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN

16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL CANCER DIAGNOSTICS

27. ONCOGENES

Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
Table of Contents (continued)
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src and others

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING CANCER DIAGNOSTICS

N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies

7B2

B72.3
Bax